CRISPR Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
CRISPR Therapeutics | DEF 14A: Definitive information statements
CRISPR Therapeutics | DEFA14A: Others
CRISPR Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: Current report
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
No Data
No Data